Randomized phase III trial on NIraparib-Dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516649-38-00

Acronym

MITO 33

Enrollment

427

Registered

2024-11-12

Start date

2020-12-01

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fallopian tube or primary peritoneal cancer, Recurrent ovarian

Brief summary

Overall Survival (OS), defined as the time from randomization to the date of death by any cause

Interventions

DRUGPACLITAXEL

DRUGDOSTARLIMAB

DRUGNIRAPARIB

DRUGTOPOTECAN

DRUGDOXORUBICIN

DRUGGEMCITABINE

DRUGBEVACIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS), defined as the time from randomization to the date of death by any cause	—

Countries

Czechia, France, Germany, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026